Diclofenac (DCLF) is a widely used non-steroidal anti-inflammatory drug that is associated with idiosyncratic, drug-induced liver injury (IDILI) in humans. The mechanisms of DCLF-induced liver injury are unknown; however, patients with certain inflammatory diseases have an increased risk of developing IDILI, which raises the possibility that immune mediators play a role in the pathogenesis. DCLF synergizes with the cytokines tumor necrosis factor-alpha (TNF) and interferon-gamma (IFN) to cause hepatocellular apoptosis in vitro by a mechanism that involves activation of the endoplasmic reticulum (ER) stress response pathway and of the mitogen-activated protein kinases, c-Jun N-terminal kinase (JNK), and extracellular signal-regulated kinase (ERK). DCLF also causes an increase in intracellular calcium (Ca þþ ) in hepatocytes, but the role of this in the cytotoxic synergy between DCLF and cytokines is unknown. We tested the hypothesis that Ca þþ contributes to DCLF/cytokine-induced cytotoxic synergy. Treatment of HepG2 cells with DCLF led to an increase in intracellular Ca þþ at 6
Drug-induced liver injury (DILI) is the leading cause of acute liver failure in the United States and the most common adverse event associated with failure to obtain U.S. Food and Drug Administration approval for new drugs (Aithal et al., 2011) . Most DILI reactions are dose-dependent and predictable using routine animal testing; however, a subset of DILI reactions is idiosyncratic. Idiosyncratic DILI (IDILI) reactions are typically rare but sometimes severe and are the most common cause of postmarketing warnings and withdrawal of drugs from the pharmaceutical market.
IDILI is a poorly understood phenomenon, but susceptibility to these reactions is likely due to actions of the drug in the context of environmental and genetic factors specific to patients (Boelsterli, 2002) . Along with antibiotics, non-steroidal antiinflammatory drugs (NSAIDs) are the most frequent causes of IDILI (Unzueta and Vargas, 2013) . The frequency and severity of IDILI among drugs differ within this pharmacologic class (Teoh and Farrell, 2003) , and patients with certain underlying diseases are susceptible to IDILI induced by some NSAIDs but not others. A retrospective cohort study found that rheumatoid arthritis was a risk factor for NSAID-induced idiosyncratic hepatotoxicity (García Rodríguez et al., 1994) . These observations further suggest that both patient-specific factors as well as drug-specific actions are important determinants of susceptibility.
Diclofenac (DCLF) is one of the most widely used NSAIDs worldwide, although its use has been restricted in the United States due to association with IDILI. The mechanisms of DCLFinduced hepatotoxicity are unknown, but immune mediators might play a role. Interestingly, osteoarthritis was found to be a risk factor for IDILI induced by DCLF in particular (Banks et al., 1995) . These observations suggest a role for inflammation in IDILI caused by NSAIDs, particularly DCLF.
Studies in rodents also revealed a role for immune mediators in DILI caused by various drugs, including DCLF (Deng et al., 2006 (Deng et al., , 2008 Dugan et al., 2011 , Shaw et al., 2009a Zou et al., 2009) . When rodents were administered a non-hepatotoxic dose of the inflammagen, lipopolysaccharide, in combination with a non-hepatotoxic dose of DCLF, they developed pronounced hepatocellular injury (Deng et al., 2006) . Similar animal models employing other IDILI-associated drugs revealed a critical role for the proinflammatory cytokines, tumor necrosis factor-alpha (TNF), and interferon-gamma (IFN), in the pathogenesis of liver injury (Dugan et al., 2011; Hassan et al., 2008; Shaw et al., 2009a, b; Zou et al., 2009) . Gene expression analysis of the livers from rodents treated with DCLF revealed increased expression of various genes involved in both the TNF and IFN signaling pathways, including TNF receptor superfamily member 1 a, signal transducer and activator of transcription-1 (STAT-1), and the tumor suppressor protein p53 (Deng et al., 2008) . The protein products of these genes are known to promote apoptosis (Gorina et al., 2005; Hussain and Harris, 2006; Shen and Pervaiz, 2006) . These findings in animals suggest that DCLF can synergize with immune mediators to cause death of hepatocytes and might explain why humans with certain underlying inflammatory diseases are more susceptible to toxicity from DCLF.
In vitro, DCLF synergized with inflammatory cytokines including TNF to kill human primary hepatocytes (Cosgrove et al., 2009) . Similarly, DCLF synergized with TNF to cause death
FIG. 1. DCLF treatment caused an increase in intracellular Ca
þþ . HepG2 cells were exposed to DCLF (250 lM) or its VEH, alone or in combination with TNF (10 ng/ml) and/or IFN (10 ng/ml) for (A) 6 or (B) 12 h. of HepG2 cells, and this depended on caspase activation and activation of the mitogen-activated protein kinase (MAPK), cJun N-terminal kinase (JNK) (Fredriksson et al., 2011) . In addition, IFN treatment enhanced cytotoxicity mediated by DCLF/TNF treatment, and this required activation of caspases, JNK, and extracellular signal-regulated kinase (ERK) (Maiuri et al., 2015) . Fredriksson et al. (2014) demonstrated that DCLF treatment caused activation of the endoplasmic reticular (ER) stress sensors, inositol requiring enzyme-1, and protein kinase RNA-like endoplasmic reticulum kinase (PERK), and this was followed by upregulation of the proapoptotic transcription factor CCAAT/-enhancer-binding protein homologous protein (CHOP). Silencing of the ER stress mediators PERK and CHOP using siRNA reduced apoptosis induced by DCLF/TNF treatment (Fredriksson et al., 2014) . These studies in vitro provided insight into the pathways activated in response to DCLF that promote a cytotoxic interaction with TNF. However, how DCLF/cytokine treatment promotes the activation of these stress-response pathways and how the pathways interact with each other in causing cell death remain unknown. It is been reported that DCLF treatment induces increases in intracellular calcium (Ca þþ ) in rat and human hepatocytes, and this contributed to cytotoxicity induced by DCLF in these cell types (Bort et al., 1999; Lim et al., 2006) . Increases in intracellular Ca þþ are known to promote the activation of MAPKs and also activation of the ER stress response pathway (Bollo et al., 2010; Kim and Sharma, 2004) . In this study, we tested the hypothesis that Ca þþ contributes to DCLF/cytokine-induced cytotoxic synergy by promoting ER stress and activation of JNK, ERK, STAT-1, and caspase 3. In addition, we explored the interdependence of DCLF-induced JNK, ERK, and STAT-1 activation. (Westerink and Schoonen, 2007a, b) . Importantly, HepG2 cells metabolize DCLF to both acylglucuronide and hydroxyl metabolites (Fredriksson et al., 2011) , which are the metabolites that have been suggested to mediate DCLF-induced hepatotoxicity (Boelsterli, 2003) . Notably, evidence supporting a role for metabolic bioactivation in DCLF-mediated hepatotoxicity in human patients is lacking (Aithal, et al., 2000) . Cells were grown in 25-cm 2 tissue culture-treated flasks, maintained in DMEM supplemented with 10% FBS and 1% ABAM (complete DMEM) and cultured at 37 C in 95% air and 5% CO 2 in a humidified incubator. They were passaged when they reached $80% confluence.
MATERIALS AND METHODS

Materials
Experimental design and cytotoxicity assessment. HepG2 cells were plated at a density of 4 Â 10 4 cells per well in black-walled, 96-well, tissue culture plates, and allowed to attach overnight before treatment with compounds. DCLF was reconstituted in sterile water. Cells were treated with 250-lM DCLF or its vehicle, and simultaneously with TNF (10 ng/ml) and/or IFN (10 ng/ml) or their vehicle (PBS). The concentrations selected were based on previous concentration response studies published in Maiuri et al. (2015) . It was demonstrated that treatment of cells with 250 lM DCLF in combination with TNF (10 ng/ml) caused a robust cytotoxic response in HepG2 cells that was enhanced by IFN (10 ng/ml), whereas treatment of cells with each component individually did not result in cell death (Maiuri et al., 2015) . The cytokine concentrations chosen for this study are within 10-fold of the concentrations found in serum of human patients undergoing an inflammatory response (Pinsky et al., 1993; Taudorf et al., 2007) . In addition, a previous time course study revealed that cytotoxicity in response to DCLF/cytokine treatment begins near 18 h and progresses until at least 24 h (Maiuri et al., 2015) . Cells treated with DCLF/cytokine combinations were also incubated in the presence or absence of the intracellular Ca or the IP3 receptor antagonist 2-aminophenoxydiphenyl borate (2-APB, 100 lM, addition simultaneous with DCLF/cytokines). The concentration of BAPTA/AM chosen was based on the observation that concentrations of BAPTA/AM ranging from 5 to 10 lM are effective in reducing intracellular free Ca þþ in stimulated HepG2 cells (Choi et al., 2014; Huang et al., 2009; Liu et al., 2004) . Cells were exposed to the drug/cytokine/inhibitor combination for 24 h, and cytotoxicity was evaluated by measuring release of lactate dehydrogenase (LDH) from the cells into culture medium using the Homogeneous Membrane Integrity Assay kit from Promega (Madison, Wisconsin). BAPTA/AM and 2-APB were reconstituted in dimethyl sulfoxide (DMSO). DMSO (0.1%) was used as the vehicle control in all experiments involving treatment with BAPTA/AM or 2-APB.
To examine the involvement of extracellular Ca þþ in the cytotoxic interaction between DCLF and cytokines, DCLF/cytokine combinations were prepared in Ca þþ -free medium. At the time of drug treatment, complete DMEM was replaced with Ca þþ -free medium, which was prepared using FBS-free and Ca þþ -free DMEM supplemented with sodium pyruvate (1 mM) and L-glutamine (4 mM). To determine if iron or reactive oxygen species (ROS) are involved in the cytotoxic interaction between DCLF and cytokines, DCLF/cytokine combinations were incubated in the presence or absence of the iron chelator, deferoxamine (DF), or the membrane permeable ROS scavenger, Tempol.
Measurement of intracellular Ca
11
. HepG2 cells were plated in 12-well tissue culture plates at a density of 6 Â 10 5 cells per well and allowed to attach overnight. 18 h after plating, HepG2 cells were treated with 250 lM DCLF or its vehicle, alone or in combination with TNF, IFN, or both. After treatment, cells were trypsinized and incubated with the Ca þþ -sensitive dye, fluo-3/AM, for 30 min. Fluo-3 fluorescence was measured using a BD FACSCanto II flow cytometer (Beckman Coulter, Brea, California). Data analysis was performed using FlowJo software (version 8.8.7, Treestar Software, Ashland, Oregon).
Caspase-3 activity. Caspase-3 activity was measured using the Caspase-3 Fluorometric Assay Kit purchased from R&D Systems (Minneapolis, Minnesota). HepG2 cells were plated at 1.2 Â 10 6 cells per well in 6-well tissue culture plates. They were treated with DCLF alone or in combination with TNF and/or IFN and also in the presence or absence of BAPTA/AM or 2-APB. For all studies involving BAPTA/AM, cells were pretreated with BAPTA/ AM for 4 h prior to the addition of DCLF and cytokines. For all studies involving 2-APB, cells were treated with 2-APB simultaneously with DCLF and cytokines. Cells were lysed and centrifuged after 24 h of exposure. 50 ll of lysate were added to blackwalled, 96-well plates and incubated with assay reaction buffer and fluorogenic substrate for 1 h. The plate was then read in a fluorescence plate reader at an excitation wavelength of 400 nm and an emission wavelength of 505 nm.
Protein isolation. Cells (1.2 Â 10 6 per well) were plated in 6-well tissue culture plates and allowed to adhere overnight. They were exposed to 250 lM DCLF and its vehicle alone or in combination with TNF and/or IFN for 18 h. For some experiments, cells treated with DCLF/cytokine combinations were also incubated in the presence of BAPTA/AM, 2-APB, or the JNK inhibitor, SP600125. SP600125 was prepared in DMSO and 0.1% DMSO was used as the vehicle control in all experiments involving treatment with SP600125. Cells were rinsed with cold PBS followed by addition of 150 ml of radioimmunoprecipitation assay buffer containing HALT protease and phosphatase inhibitor cocktails (Thermo Scientific, Rockford, Illinois). Cells were scraped, collected, placed in microcentrifuge tubes, and incubated on ice for 10 min. During the 10-min incubation, the tubes were vortexed intermittently. Lysates were centrifuged for 25 min at 20 000 Â g. The supernatant fluids containing whole cell protein were collected and stored at À80 C until use. Protein concentrations were quantified using the bicinchoninic acid assay (Thermo Scientific).
Western analysis. For detection of phosphorylated JNK (pJNK), phosphorylated ERK (pERK), phosphorylated PERK (pPERK), and phosphorylated STAT-1 (pSTAT-1) in whole cell lysates, 25 lg protein were loaded onto precast NuPAGE 12% Bis-Tris gels (Life Technologies), and subjected to electrophoresis. Proteins were transferred onto polyvinylidene fluoride membranes (Millipore). Membranes were blocked for 1 h with 5% bovine serum albumin (BSA) reconstituted in 1% tris-buffered saline (TBS) containing 0.1% tween-20 (TBSt). They were then probed with antibodies directed against pJNK, pERK, pPERK, pSTAT-1 (tyrosine 701), pSTAT-1 (serine 727), and a-tubulin. Primary antibodies were diluted in 2% BSA in TBSt. Membranes were incubated with primary antibodies overnight at 4 C, after which they were washed with TBSt followed by the addition of secondary antibody. Goat anti-rabbit or goat anti-mouse horseradish peroxidase (HRP)-conjugated secondary antibody was diluted in 5% BSA in TBSt at a concentration of 1:2500 for pJNK and 1:5000 for all others. Clarity Western ECL substrate (Bio-Rad, Hercules, California) was used to visualize HRP, and the substrate was developed on HyBlot CL film (Denville Scientific, Metuchen, New Jersey). All images were quantified by performing densitometry using Image J software.
Statistical analysis. All results are expressed as mean 6 standard error of the mean (SEM). Data were subjected to log transformation as necessary to achieve equal variance and normality. Data were analyzed by either a 1-way or 2-way analysis of variance (ANOVA), as appropriate. For 1-way and 2-way ANOVAs, the Holm-Sidak post hoc test was used for multiple, pair-wise comparisons between treatment groups. The criterion for significance was set at a ¼ 0.05.
RESULTS
DCLF Promotes an Increase in Cytosolic Free Ca
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Ca þþ levels were measured at 2 times prior to the onset of cytotoxicity. Treatment of cells with TNF did not promote an increase in intracellular calcium at the times examined. Treatment with IFN promoted an increase in intracellular Ca þþ at 6 h but not at 12 h. Treatment with DCLF caused an increase in intracellular Ca þþ at 6 h that was still apparent at 12 h.
Interestingly, the DCLF-induced increase in intracellular Ca þþ at 12 h was enhanced by treatment with TNF/IFN (Figure 1 ). with IFN alone, IFN enhanced the cytotoxic interaction between DCLF and TNF. Pretreatment of cells with the intracellular Ca þþ chelator BAPTA/AM had no effect on LDH release from VEH/ Control-treated cells but markedly reduced cytotoxicity induced by DCLF/TNF treatment, as well as the IFN-mediated enhancement of DCLF/TNF-induced cytotoxicity (Figure 2A ). DCLF/TNF-induced cytotoxicity and the IFN-mediated enhancement of this cytotoxicity are caspase-dependent (Fredriksson et al., 2011; Maiuri et al., 2015) . BAPTA/AM pretreatment markedly reduced DCLF/cytokine-induced caspase-3 activation, suggesting that Ca þþ released from an intracellular source contributes to DCLF/cytokine-induced apoptosis ( Figure  2B ). In contrast, incubating cells in culture medium depleted of Ca þþ did not significantly alter the DCLF/cytokine-induced cytotoxic interaction, suggesting that extracellular Ca þþ is not important in the cytotoxic interaction (Supplementary Figure 1) . BAPTA/AM has been reported to have iron-chelating activities (Britigan and Rasmussen, 1998) ; accordingly, a potential role for iron in DCLF/cytokine-induced cytotoxicity was assessed. Furthermore, since ROS can be generated through iron-catalyzed reactions, we also evaluated a potential contribution of ROS to the DCLF/cytokine interaction. Cytotoxicity induced by treatment with DCLF/cytokines was unaffected by inclusion of either deferoxamine to chelate iron or Tempol to scavenge ROS (Supplementary Figure 2 ).
An Intracellular Ca
An IP3 Receptor Antagonist Reduces Cytotoxicity Induced by DCLF/ Cytokine Cotreatment
The ER is widely known for its role in intracellular Ca þþ sequestration, and Ca þþ can be released from the ER via activation of IP3 receptors located on the ER membrane. Treatment of HepG2 cells with 2-APB, an IP3 receptor antagonist, almost completely eliminated DCLF/TNF-induced cytotoxicity as well as the IFNmediated enhancement of cytotoxicity ( Figure 3A ). In addition, treatment of HepG2 cells with 2-APB markedly reduced DCLF/ cytokine-induced caspase-3 activation ( Figure 3B ). Figures 4A and B) . Treatment with DCLF led to phosphorylation of PERK, and this was unaffected by addition of TNF and/or IFN. Treatment with either BAPTA/AM ( Figure 4A ) or 2-APB ( Figure 4B ) significantly decreased the activation of PERK. Ca 11 Contributes to DCLF-Mediated JNK Activation DCLF/TNF-mediated cytotoxicity and the IFN-mediated enhancement of that cytotoxicity are JNK-dependent processes (Fredriksson et al., 2011; Maiuri et al., 2015) . DCLF caused activation of JNK at 18 hours, consistent with previous findings, and this effect was unaltered by cytokine treatment (Figures 5A and B) . DCLF/cytokinemediated JNK activation was reduced by pretreatment with BAPTA/AM ( Figure 5A ) and by treatment with 2-APB ( Figure 5B ).
Ca 11 Contributes to DCLF-Mediated ERK Activation
The IFN-mediated enhancement of DCLF/TNF-induced cytotoxicity depends on ERK (Maiuri et al., 2015) . DCLF treatment promoted strong activation of ERK that was unaffected by cytokine treatment (Figure 6 ), confirming our earlier observation. Pretreatment of cells with BAPTA/AM significantly reduced ERK activation induced by DCLF ( Figure 6A ). Similarly, treatment of HepG2 cells with 2-APB markedly reduced DCLF-mediated activation of ERK ( Figure 6B ). (Varinou et al., 2003) . We demonstrated previously that DCLF-mediated ERK activation promotes phosphorylation of STAT-1 at Ser 727 in the presence of IFN and that the IFN-mediated enhancement of DCLF/TNF-induced cytotoxicity is driven by ERK (Maiuri et al., 2015) . Since Ca Figure 8A ). Moreover, treatment with SP600125 significantly reduced DCLF-induced activation of ERK ( Figure 8B ).
Aspirin Does Not Promote Activation of JNK or ERK, or the ER Stress Sensor, PERK
The results above suggest that DCLF-induced activation of JNK, ERK, and the ER stress sensor PERK is required for cytotoxic synergy mediated by DCLF/cytokine cotreatment. Aspirin is an NSAID that is not associated with human IDILI, and it does not synergize with cytokines to kill HepG2 cells (Maiuri et al., 2015) .
To evaluate the specificity of the IDILI-associated drug DCLF in activating these pathways, we evaluated whether aspirin treatment promotes activation of JNK, ERK, and PERK. The concentration of aspirin chosen relative to its maximal plasma concentration observed in human patients (C max ) is comparable to that chosen for DCLF relative to its C max (Brandon et al., 1986; Xu et al., 2008) . Treatment of HepG2 cells with aspirin did not result in activation of any of these factors (Figure 9 ).
DISCUSSION
We and others have shown that DCLF synergizes with cytokines to cause cytotoxicity in human primary hepatocytes (Cosgrove et al., 2009 ) and HepG2 cells (Fredriksson et al., 2011; Maiuri et al., 2015) by a mechanism involving the MAPKs, JNK, and ERK. Moreover, Fredriksson et al. (2014) reported that DCLF caused activation of the ER stress pathway in HepG2 cells as early as 2 h after treatment, and this response was unaffected by TNF but was required for DCLF/TNF-induced cytotoxic synergy. In addition, DCLF induced a delayed increase in intracellular Ca þþ in transformed human hepatocytes after 6 h of exposure (Lim et al., 2006) . Moreover, others have shown that cytokine treatment can also promote an increase in intracellular Ca þþ (Chang et al., 2004; Delmotte et al., 2012) . Similarly, we demonstrated in HepG2 cells that DCLF promotes a delayed increase in intracellular Ca þþ , and this increase was enhanced by treatment with TNF/IFN (Figure 1 ). Since ER stress is strongly associated with promoting increases in intracellular Ca þþ , and since DCLF treatment can induce both of these responses in liver cells, we hypothesized that Ca þþ contributes to DCLF/cytokine-induced cytotoxic synergy. Chelation of intracellular Ca þþ markedly reduced cytotoxicity and caspase-3 activation induced by DCLF/cytokine treatment (Figure 2 ), whereas removal of extracellular Ca þþ did not affect the cytotoxic interaction (Supplementary Figure 1) . These findings suggest that Ca þþ released from an intracellular source underlies the cytotoxic interaction mediated by DCLF/cytokine cotreatment. Ca þþ is primarily stored in the ER, but it can also be stored in other intracellular compartments including the mitochondria (Berridge et al., 1998) . Ryanodine receptors and IP3 receptors are the most well-characterized Ca þþ channels localized to the ER membrane. Moreover, IP3 receptor activation is associated with Ca þþ -mediated apoptosis via the intrinsic (mitochondrial) pathway (Deniaud et al., 2008; Verrier et al., 2004) . 2-APB, a commonly used IP3 receptor antagonist, greatly reduced the cytotoxic interaction mediated by DCLF/TNF cotreatment, prevented the IFN-mediated enhancement of cytotoxicity, and reduced DCLF/ cytokine-induced caspase-3 activation (Figure 3 ), suggesting that these responses require IP3 receptor activation. This receptor is typically activated by IP3 released from membranes by phospholipase C. Whether DCLF can activate a phospolipase C isozyme or directly activate the IP3 receptor remains to be determined. Activation of PERK, a component of the ER stress-response pathway, contributed to cytotoxicity mediated by DCLF/TNF (Fredriksson et al., 2014) . Although treatment with TNF did not affect the activation of PERK (Fredriksson et al., 2014) , the participation of IFN in activation of PERK had not been investigated. As observed with TNF, IFN did not modulate the activation of PERK in response to DCLF treatment (Figure 4) . It is well understood that ER stress can cause increases in intracellular Ca þþ . Conversely, elevated intracellular Ca þþ can engage in a feedback amplification loop, thereby promoting persistent activation of the ER stress pathway (Timmins et al., 2009) . Treatment with either BAPTA/AM or 2-APB reduced DCLF-induced PERK activation. These findings indicate that intracellular free Ca þþ contributes to persistent ER stress in response to DCLF exposure. DCLF/cytokine-induced cytotoxic synergy requires JNK (Fredriksson et al., 2011; Maiuri et al., 2015) . JNK is activated in response to a variety of stressors, including TNF exposure, UV radiation, ROS, ER stress, and increased intracellular Ca þþ (Kim and Sharma, 2004; Seki et al., 2012) . The kinetics of the activation of JNK can vary depending on the inducer, and the duration of JNK activation is critical to determining the fate of a cell. For instance, TNF promotes transient activation of JNK, which is associated with cell survival. Other stressors that induce persistent activation of JNK are associated with caspase activation and apoptosis (Seki et al., 2012) . TNF modestly activated JNK at 12 h after treatment in HepG2 cells, and this response was transient in the absence of DCLF. In contrast, in the presence of DCLF, JNK activation persisted until at least 18 h (Maiuri et al., 2015) . The mechanism by which DCLF promotes persistent activation of JNK appears to involve ER stress and elevated intracellular Ca þþ , since BAPTA/AM and 2-APB reduced activation of JNK in response to DCLF ( Figure 5 ). Since 2-APB also greatly reduced cytotoxicity induced by DCLF/cytokine cotreatment, these results are consistent with our previous findings which suggested that JNK is necessary for DCLF/cytokine-induced cytotoxic synergy (Maiuri et al., 2015) . Ca þþ can lead to activation of JNK via several routes, one of which involves activation of Ca þþ /calmodulin-dependent protein kinase II (CaMKII) in response to ER stress. CaMKII can directly phosphorylate apoptosis signal-regulating kinase 1, a MAPK kinase kinase (MAPKKK) that promotes downstream sustained activation of JNK (Brnjic et al., 2010) . Taken together, these findings indicate that DCLF-mediated activation of JNK requires availability of Ca þþ . Furthermore, IP3-mediated release of Ca þþ from the ER drives DCLF-induced JNK activation.
The IFN-mediated enhancement of DCLF/TNF-induced cytotoxicity involves ERK (Maiuri et al., 2015) . DCLF treatment caused activation of ERK as early as 12 h; this persisted until after 18 h and was unaffected by TNF and/or IFN treatment (Maiuri et al., 2015) . The observation that both BAPTA/AM and 2-APB reduced ERK activation ( Figure 6) (Li et al., 2005) . Activation of STAT-1 plays an important role in IFN-dependent apoptosis (Cao et al., 2015) . Dual phosphorylation of STAT-1 is required for maximal activation (Varinou et al., 2003) , and this occurred in cells treated with DCLF/IFN but not in cells treated with IFN or DCLF alone (Maiuri et al., 2015 and Figure 7) . Not surprisingly, treatment of HepG2 cells with IFN caused phosphorylation of STAT-1 at Tyr 701 (Maiuri et al., 2015 and Figure 7 ) presumably via activation of JAK (Schroder et al., 2004) . DCLF in the presence of IFN promoted phosphorylation of STAT-1 at Ser 727 via activated ERK (Maiuri et al., 2015) . Consistent with their effects on DCLF-induced ERK activation, treatment with either BAPTA/AM or 2-APB reduced DCLF/IFN-induced phosphorylation of STAT-1 at Ser 727 (Figure 7) . These results indicate that cytoplasmic-free Ca þþ contributes to STAT-1 activation induced by DCLF/IFN cotreatment. Interestingly, treatment with BAPTA/ AM or 2-APB did not affect IFN-induced phosphorylation of STAT-1 at Tyr 701 ( Figure 7 ). JNK can also phosphorylate STAT-1 at Ser 727 (Zhang et al., 2004) . Indeed, treatment of HepG2 cells with a JNK inhibitor eliminated the IFN-mediated enhancement of DCLF/TNF-induced cytotoxicity, suggesting that, along with ERK, JNK drives the IFN component of the DCLF/cytokine interaction (Maiuri et al., 2015) . Treatment with the JNK inhibitor SP600125 eliminated DCLF/ IFN-induced phosphorylation of STAT-1 at Ser 727 without affecting IFN-mediated phosphorylation of STAT-1 at Tyr 701 ( Figure 8A ). These results indicate that in addition to ERK, JNK mediates activation of STAT-1 in response to DCLF/IFN and raise the question, does JNK contribute to the activation of ERK in response to DCLF treatment? The kinetics of DCLF-induced JNK activation were similar to the kinetics of DCLF-induced ERK activation (Maiuri et al., 2015) . Treatment with SP600125 reduced DCLF-induced ERK activation ( Figure 8B ), suggesting that JNK is involved in the activation of ERK in response to DCLF treatment but is not solely responsible for it. In addition, these results raise the possibility that JNK contributes to the phosphorylation of STAT-1 at Ser 727 by promoting the activation of ERK.
We and others have shown that aspirin, an NSAID not associated with IDILI, does not synergize with cytokines to kill primary human hepatocytes (Cosgrove et al., 2009) or HepG2 cells (Maiuri et al., 2015) . Unlike DCLF, treatment with aspirin did not induce activation of PERK, JNK, or ERK (Figure 9 ). Thus, in the absence of activation of these pathways, no cytotoxicity was observed, and when they were activated, cytotoxicity occurred. These observations lend support to the conclusion that activation of PERK, JNK, and ERK plays a critical role in the cytotoxic DCLF/cytokine interaction and support the possibility that NSAID-mediated IDILI involves activation of ER stress and MAPK pathways in hepatocytes.
The molecular mechanisms by which DCLF initiates activation of the ER stress pathway remain unknown. It is possible that DCLF directly or indirectly promotes activation of phospholipase C leading to formation of IP3, which causes IP3 receptor (IP3R)-mediated release of Ca þþ from the ER. This could lead to elevated cytoplasmic Ca þþ and ER stress. Another possibility is that DCLF inhibits proteasomal degradation of proteins, leading to accumulation of proteins in the ER. Indeed, several IDILIassociated drugs can cause ER stress by inhibiting the ubiquitinproteasome pathway. For instance, efavirenz, ritonavir, and lopinavir, antiretroviral drugs associated with IDILI, induced ER stress in primary human and transformed hepatocytes by inhibiting the proteasome (Apostolova, 2013; Kao et al., 2012) . Moreover, several protease inhibitors used for the treatment of HIV induced activation of CHOP, activating transcription factor-4, and several other ER stress markers in human HepG2 cells by inhibiting the proteasome (Parker et al., 2005) . Additional studies are needed to elucidate the molecular mechanisms underlying DCLF-induced activation of the ER stress pathway. It was shown previously that a large concentration of DCLF promotes mitochondrial permeability transition leading to death of hepatocytes in vitro, and this was initiated by an increase in intracellular Ca þþ (Lim et al., 2006) . Although the role of mitochondrial permeability transition in the cytotoxic interaction between DCLF and cytokines has not been examined directly, results from a previous study suggest that it might be involved. Specifically, the observation that siRNA-mediated silencing of components of the apoptosome protected HepG2 cells from DCLF/TNF-induced cytotoxicity raised the possibility that mitochondrial permeability transition occurs, releasing cytochrome c into the cytosol to initiate the intrinsic pathway of apoptosis (Fredriksson et al., 2011) . Furthermore, in our study Ca þþ release contributed to sustained activation of JNK, a phenomenon that is well known to promote mitochondrial permeability transition and cell death. Therefore, our findings are consistent with what has been demonstrated previously with regard to DCLF-mediated induction of mitochondrial permeability transition and its role in death of hepatocytes. Collectively, these findings indicate that availability of Ca þþ in the cytoplasm, likely due to release from the ER via IP3 receptor stimulation, underlies most, if not all, aspects of DCLF/cytokine-induced cytotoxic synergy. This raises the possibility that increased intracellular Ca þþ contributes to hepatocellular injury that occurs in cases of human IDILI. Finally, results from this study together with previous findings tie together critical components of the mechanism underlying the cytotoxic interaction mediated by DCLF and cytokines (summarized in Figure 10 ).
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SUPPLEMENTARY DATA
Supplementary data are available online at http://toxsci.oxfordjournals.org/. DCLF treatment causes early activation of the ER stress response pathway (Fredriksson et al., 2014) . ER stress results in release of Ca þþ from the ER via IP3
receptors, leading to an increase in cytoplasmic free Ca þþ (Deniaud et al., 2008) .
Ca þþ released from the ER during ER stress can participate in a feedback amplification loop, leading to persistent ER stress, which is known to be associated with apoptosis (Timmins et al., 2009) . Consistent with its induction of the ER stress pathway, DCLF treatment caused an increase in intracellular Ca þþ .
Although not shown in the diagram, TNF/IFN treatment caused a delayed enhancement of the DCLF-mediated increase in intracellular Ca þþ . The increase in intracellular free Ca þþ contributes to the cytotoxic DCLF/cytokine interaction not only by contributing to persistent ER stress but also by activating JNK and ERK. TNF treatment causes modest, early activation of JNK that is transient in the absence of DCLF but persistent in its presence (Maiuri et al., 2015) . Persistent activation of JNK is essential for DCLF/TNF-induced apoptosis presumably by contributing to mitochondrial permeability transition (Fredriksson et al., 2011; Lim et al., 2006) .DCLF-induced activation of JNK contributes to activation of ERK which plays a role in the IFN-mediated enhancement of DCLF/TNF-induced cytotoxicity (Maiuri et al., 2015) . IFN alone leads to phosphorylation of STAT-1 at Tyr 701 which allows translocation of STAT-1 from the cytoplasm to the nucleus. Translocation allows STAT-1 to be phosphorylated at Ser 727 (Sadzak et al. 2008 ), leading to full activation. In our model, dual phosphorylation of STAT-1 occurs through exposure to IFN only in the presence of DCLF and is mediated through ERK which is activated in response to DCLF. Full STAT-1 activation enhances apoptosis caused by the interaction of DCLF and TNF.
Abbreviations: ER, endoplasmic reticulum; IP3R, inositol trisphosphate receptor; Ca þþ , calcium; JNK, c-Jun N-terminal kinase; TNF, tumor necrosis factor-alpha;
ERK, extracellular signal-regulated kinase; STAT-1, signal transducer and activator of transcription; S727, serine 727; T701, tyrosine 701; IFN, interferon gamma.
